A large “de-escalation” trial suggests that tens of thousands of people annually may be able to rely on only chemotherapy and surgery to treat their illness. By Gina Kolata For some patients ...
But within its labs Organon had developed a little-noticed PD1-targeting antibody it called lambrolizumab. By the time Merck absorbed Organon, lambrolizumab wasn’t a high priority and, according to ...